HCPLive Network

Hepatitis C

Company is seeking FDA approval for its all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 hepatitis C.
New guidance from the WHO includes nine key recommendations covering screening, treatment, alcohol use assessment and counseling, and measures to prevent transmission of the virus.
A large multinational observational study of patients with hepatitis C reveals etiology does not play a major role in HCV survival rates and that early detection and access to treatment have a greater impact.
Preliminary results from the M12-999 study show that treatment with ABT-450/ritonavir/ombitasvir plus dasabuvir and ribavirin is well tolerated and associated with high rates of sustained virologic response in adult liver transplant recipients with recurrent HCV genotype 1 infection.
Results from the phase III ION-2 study show a 24-week regimen of sofosbuvir/ledipasvir does not produce significantly better cure rates than a 12-week regimen in treatment-experienced patients.
Results from the SAPPHIRE-I trial show that Abbvie’s 3D therapy produced 96% sustained viral response rates at 12 weeks in treatment-naive patient with genotype 1 hepatitis C.
Hepatitis C Upcoming Events